Page 27 - Compass Pathways News Today

Investegate announcements from COMPASS Pathways, COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

Capitalism is tripping over itself to get people tripping on legal psychedelics.

Previously relegated to underground communities and raves, ketamine, MDMA and psilocybin are now being studied to develop therapies to treat everything from PTSD to cluster headaches.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Following a 40-year hiatus, research and development into the potential applications of psychedelic medicines has resurfaced. This article considers avenues to protect psychedelic companies' intellectual property and their investment in research and development. Rising research activity has already led to an increase in patent filings for psychedelics in recent years, but this article also considers the need for a varied portfolio of IP rights, potentially utilising the protection offered to...

/PRNewswire/ -- Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in magic mushrooms. Authorities plan to...

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, April 28, 2022 /PRNewswire/ -- Oregon is set to become the first US state to market legal psilocybin, the psychoactive

/PRNewswire/ -- Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in magic mushrooms. Authorities plan to...

Investegate announcements from COMPASS Pathways, COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

Various studies have been done showing that psilocybin, the primary psychoactive chemical in magic mushrooms, can greatly reduce the symptoms of major... 19.04.2022, Sputnik International